Substance list · California
Suggested substance list
- Entries
- 1015
- Version date
- 2026-07-31
- Guide
- California
Entries 1 to 500 of 1015
500 rows
| Substance | English name | CAS | Type | Category | Threshold | Conditions | Valid |
|---|---|---|---|---|---|---|---|
| A-alpha-C (2-Amino-9H-pyrido[2,3-b]indole) | A-alpha-C (2-Amino-9H-pyrido[2,3-b]indole) | 26148-68-5 | substance | cancer | 2 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | |
| Abiraterone acetate | Abiraterone acetate | 154229-18-2 | substance | developmental, female, male | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 2016-04-08 | |
| Acetaldehyde | Acetaldehyde | 75-07-0 | substance | cancer | 90 (inhalation) µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-04-01 | |
| Acetamide | Acetamide | 60-35-5 | substance | cancer | 10 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | |
| Acetazolamide | Acetazolamide | 59-66-5 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1999-08-20 | |
| Acetochlor | Acetochlor | 34256-82-1 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-01-01 | |
| Acetohydroxamic acid | Acetohydroxamic acid | 546-88-3 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1990-04-01 | |
| 2-Acetylaminofluorene | 2-Acetylaminofluorene | 53-96-3 | substance | cancer | 0.2 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-07-01 | |
| Acifluorfen sodium | Acifluorfen sodium | 62476-59-9 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | |
| Acrylamide | Acrylamide | 79-06-1 | substance | cancer | 0.2 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | |
| Acrylamide | Acrylamide | 79-06-1 | substance | developmental, male | 140 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2011-02-25 | |
| Acrylonitrile | Acrylonitrile | 107-13-1 | substance | cancer | 0.7 µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1987-07-01 | |
| Actinomycin D [Basis for listing changed effective February 22, 2013] | Actinomycin D [Basis for listing changed effective February 22, 2013] | 50-76-0 | substance | cancer | 0.00008 µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1989-10-01 | |
| Actinomycin D | Actinomycin D | 50-76-0 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1992-10-01 | |
| AF-2;[2-(2-furyl)-3-(5-nitro-2-furyl)]acrylamide | AF-2;[2-(2-furyl)-3-(5-nitro-2-furyl)]acrylamide | 3688-53-7 | substance | cancer | 3 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-07-01 | |
| Aflatoxins | Aflatoxins | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | CAS column: "---" | ||
| Alachlor | Alachlor | 15972-60-8 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-01-01 | |
| Alcoholic beverages | Alcoholic beverages | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2011-04-29 | CAS column: "---" | ||
| Alcoholic beverages, when associated with alcohol abuse | Alcoholic beverages, when associated with alcohol abuse | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-07-01 | CAS column: "---" | ||
| Aldrin | Aldrin | 309-00-2 | substance | cancer | 0.04 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-07-01 | |
| All-trans retinoic acid | All-trans retinoic acid | 302-79-4 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-01-01 | |
| Allyl chloride | Allyl chloride | 107-05-1 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | Delisted: October 29, 1999 | until 1999-10-29 |
| Aloe vera, non-decolorized whole leaf extract | Aloe vera, non-decolorized whole leaf extract | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2015-12-04 | CAS column: "---" | ||
| Alprazolam | Alprazolam | 28981-97-7 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1990-07-01 | |
| Altretamine | Altretamine | 645-05-6 | substance | developmental, male | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1999-08-20 | |
| Amantadine hydrochloride | Amantadine hydrochloride | 665-66-7 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 2001-02-27 | |
| Amikacin sulfate | Amikacin sulfate | 39831-55-5 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1990-07-01 | |
| 2-Aminoanthraquinone | 2-Aminoanthraquinone | 117-79-3 | substance | cancer | 20 µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 1989-10-01 | |
| p-Aminoazobenzene | p-Aminoazobenzene | 60-09-3 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | |
| o-Aminoazotoluene | o-Aminoazotoluene | 97-56-3 | substance | cancer | 0.2 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-07-01 | |
| 4-Aminobiphenyl (4-aminodiphenyl) | 4-Aminobiphenyl (4-aminodiphenyl) | 92-67-1 | substance | cancer | 0.03 µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 1987-02-27 | |
| 2-Amino-4-chlorophenol | 2-Amino-4-chlorophenol | 95-85-2 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2019-09-13 | |
| 1-Amino-2,4-dibromoanthraquinone | 1-Amino-2,4-dibromoanthraquinone | 81-49-2 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1997-08-26 | |
| 3-Amino-9-ethylcarbazole hydrochloride | 3-Amino-9-ethylcarbazole hydrochloride | 6109-97-3 | substance | cancer | 9 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-07-01 | |
| 2-Aminofluorene | 2-Aminofluorene | 153-78-6 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1999-01-29 | |
| Aminoglutethimide | Aminoglutethimide | 125-84-8 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1990-07-01 | |
| Aminoglycosides | Aminoglycosides | other | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1992-10-01 | CAS column: "---" | ||
| 1-Amino-2-methylanthraquinone | 1-Amino-2-methylanthraquinone | 82-28-0 | substance | cancer | 5 µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 1989-10-01 | |
| 2-Amino-5-(5-nitro-2-furyl)-1,3,4-thiadiazole | 2-Amino-5-(5-nitro-2-furyl)-1,3,4-thiadiazole | 712-68-5 | substance | cancer | 0.04 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-07-01 | |
| 4-Amino-2-nitrophenol | 4-Amino-2-nitrophenol | 119-34-6 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1999-01-29 | |
| Aminopterin | Aminopterin | 54-62-6 | substance | developmental, female | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-07-01 | |
| Amiodarone hydrochloride | Amiodarone hydrochloride | 19774-82-4 | substance | developmental, female, male | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1997-08-26 | |
| Amitraz | Amitraz | 33089-61-1 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1999-03-30 | |
| Amitrole | Amitrole | 61-82-5 | substance | cancer | 0.7 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-07-01 | |
| Amoxapine | Amoxapine | 14028-44-5 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1998-05-15 | |
| Amsacrine | Amsacrine | 51264-14-3 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2009-08-07 | |
| tert-Amyl methyl ether | tert-Amyl methyl ether | 994-05-8 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2009-12-18 | Delisted: December 13, 2013 | until 2013-12-13 |
| Anabolic steroids | Anabolic steroids | other | female, male | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1990-04-01 | CAS column: "---" | ||
| Analgesic mixtures containing Phenacetin | Analgesic mixtures containing Phenacetin | group | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 1987-02-27 | CAS column: "---" | ||
| Androstenedione | Androstenedione | 63-05-8 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2011-05-03 | |
| Angiotensin converting enzyme (ACE) inhibitors | Angiotensin converting enzyme (ACE) inhibitors | other | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1992-10-01 | CAS column: "---" | ||
| Aniline | Aniline | 62-53-3 | substance | cancer | 100 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | |
| Aniline hydrochloride | Aniline hydrochloride | 142-04-1 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1998-05-15 | |
| o-Anisidine | o-Anisidine | 90-04-0 | substance | cancer | 5 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-07-01 | |
| o-Anisidine hydrochloride | o-Anisidine hydrochloride | 134-29-2 | substance | cancer | 7 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-07-01 | |
| Anisindione | Anisindione | 117-37-3 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1992-10-01 | |
| Anthracene | Anthracene | 120-12-7 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2023-08-11 | |
| Anthraquinone | Anthraquinone | 84-65-1 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2007-09-28 | |
| Antimony oxide (Antimony trioxide) | Antimony oxide (Antimony trioxide) | 1309-64-4 | substance | cancer | 0.13 (inhalation) µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-10-01 | |
| Aramite | Aramite | 140-57-8 | substance | cancer | 20 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-07-01 | |
| Areca nut | Areca nut | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2006-02-03 | CAS column: "---" | ||
| Aristolochic acids | Aristolochic acids | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2004-07-09 | CAS column: "---" | ||
| Arsenic (inorganic arsenic compounds) | Arsenic (inorganic arsenic compounds) | group | cancer | 0.06 (inhalation) 10 (except inhalation) µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 1987-02-27 | CAS column: "--" | ||
| Arsenic (inorganic oxides) | Arsenic (inorganic oxides) | other | developmental | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1997-05-01 | CAS column: "---" | ||
| Asbestos | Asbestos | 1332-21-4 | substance | cancer | 100 fibers/day (inhalation) µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 1987-02-27 | |
| Aspirin (NOTE: It is especially important not to use aspirin during the last three months of pregnancy, unless specifically directed to do so by a physician because it may cause problems in the unborn child or complications during delivery.) | Aspirin (NOTE: It is especially important not to use aspirin during the last three months of pregnancy, unless specifically directed to do so by a physician because it may cause problems in the unborn child or complications during delivery.) | 50-78-2 | substance | developmental, female | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1990-07-01 | |
| Atenolol | Atenolol | 29122-68-7 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1997-08-26 | |
| Atrazine | Atrazine | 1912-24-9 | substance | developmental, female | 100 (oral) µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2016-07-15 | |
| Auramine | Auramine | 492-80-8 | substance | cancer | 0.8 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-07-01 | |
| Auranofin | Auranofin | 34031-32-8 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1999-01-29 | |
| Avermectin B1 (Abamectin) | Avermectin B1 (Abamectin) | 71751-41-2 | substance | developmental | 4.4 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2010-12-03 | |
| Azacitidine | Azacitidine | 320-67-2 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1992-01-01 | |
| Azaserine | Azaserine | 115-02-6 | substance | cancer | 0.06 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-07-01 | |
| Azathioprine | Azathioprine | 446-86-6 | substance | cancer | 0.4 µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 1987-02-27 | |
| Azathioprine | Azathioprine | 446-86-6 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1996-09-01 | |
| Azobenzene | Azobenzene | 103-33-3 | substance | cancer | 6 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | |
| Barbiturates | Barbiturates | other | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1992-10-01 | CAS column: "---" | ||
| Beclomethasone dipropionate | Beclomethasone dipropionate | 5534-09-8 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1998-05-15 | |
| Benomyl | Benomyl | 17804-35-2 | substance | developmental, male | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1991-07-01 | |
| Benthiavalicarb-isopropyl | Benthiavalicarb-isopropyl | 177406-68-7 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2008-07-01 | |
| Benz[a]anthracene | Benz[a]anthracene | 56-55-3 | substance | cancer | 0.033 (oral) µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-07-01 | |
| Benzene | Benzene | 71-43-2 | substance | cancer | 6.4 (oral) 13 (inhalation) µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 1987-02-27 | |
| Benzene | Benzene | 71-43-2 | substance | developmental, male | 24 (oral) 49 (inhalation) µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1997-12-26 | |
| Benzidine [and its salts] | Benzidine [and its salts] | 92-87-5 | substance | cancer | 0.001 µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 1987-02-27 | |
| Benzidine-based dyes | Benzidine-based dyes | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1992-10-01 | CAS column: "---" | ||
| Benzodiazepines | Benzodiazepines | other | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1992-10-01 | CAS column: "---" | ||
| Benzo[b]fluoranthene | Benzo[b]fluoranthene | 205-99-2 | substance | cancer | 0.096 (oral) µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-07-01 | |
| Benzo[j]fluoranthene | Benzo[j]fluoranthene | 205-82-3 | substance | cancer | 0.11 (oral) µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-07-01 | |
| Benzo[k]fluoranthene | Benzo[k]fluoranthene | 207-08-9 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-07-01 | |
| Benzofuran | Benzofuran | 271-89-6 | substance | cancer | 1.1 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-10-01 | |
| Benzophenone | Benzophenone | 119-61-9 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2012-06-22 | |
| Benzo[a]pyrene | Benzo[a]pyrene | 50-32-8 | substance | cancer | 0.06 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-07-01 | |
| Benzotrichloride | Benzotrichloride | 98-07-7 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-07-01 | |
| Benzphetamine hydrochloride | Benzphetamine hydrochloride | 5411-22-3 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1990-04-01 | |
| Benzyl chloride | Benzyl chloride | 100-44-7 | substance | cancer | 4 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | |
| Benzyl violet 4B | Benzyl violet 4B | 1694-09-3 | substance | cancer | 30 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-07-01 | |
| Beryllium and beryllium compounds | Beryllium and beryllium compounds | group | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-10-01 | CAS column: "---" | ||
| Beryllium | Beryllium | other | cancer | 0.1 µg/day (NSRL or MADL) | Sub entry under "Beryllium and beryllium compounds" giving a safe harbor level for this member or population; type of toxicity, listing mechanism and date listed are those of the parent entry | ||
| Beryllium oxide | Beryllium oxide | other | cancer | 0.1 µg/day (NSRL or MADL) | Sub entry under "Beryllium and beryllium compounds" giving a safe harbor level for this member or population; type of toxicity, listing mechanism and date listed are those of the parent entry | ||
| Beryllium sulfate | Beryllium sulfate | other | cancer | 0.0002 µg/day (NSRL or MADL) | Sub entry under "Beryllium and beryllium compounds" giving a safe harbor level for this member or population; type of toxicity, listing mechanism and date listed are those of the parent entry | ||
| Betel quid with tobacco | Betel quid with tobacco | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | CAS column: "---" | ||
| Betel quid without tobacco | Betel quid without tobacco | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2006-02-03 | CAS column: "---" | ||
| Bevacizumab | Bevacizumab | 216974-75-3 | substance | developmental, female | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 2019-03-08 | |
| 2,2-Bis(bromomethyl)-1,3-propanediol | 2,2-Bis(bromomethyl)-1,3-propanediol | 3296-90-0 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1996-05-01 | |
| Bis(2-chloroethyl)ether | Bis(2-chloroethyl)ether | 111-44-4 | substance | cancer | 0.3 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-04-01 | |
| N,N-Bis(2-chloroethyl)-2-naphthylamine (Chlornapazine) | N,N-Bis(2-chloroethyl)-2-naphthylamine (Chlornapazine) | 494-03-1 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 1987-02-27 | |
| Bischloroethyl nitrosourea (BCNU) (Carmustine) | Bischloroethyl nitrosourea (BCNU) (Carmustine) | 154-93-8 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-07-01 | |
| Bischloroethyl nitrosourea (BCNU) (Carmustine) | Bischloroethyl nitrosourea (BCNU) (Carmustine) | 154-93-8 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1990-07-01 | |
| Bis(chloromethyl)ether | Bis(chloromethyl)ether | 542-88-1 | substance | cancer | 0.02 µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 1987-02-27 | |
| Bis(2-chloro-1-methylethyl)ether, technical grade | Bis(2-chloro-1-methylethyl)ether, technical grade | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1999-10-29 | CAS column: "---" | ||
| Bisphenol A (BPA) | Bisphenol A (BPA) | 80-05-7 | substance | female | 3 (dermal exposure from solid materials) µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 2015-05-11 | |
| Bisphenol A (BPA) | Bisphenol A (BPA) | 80-05-7 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2020-12-18 | |
| Bisphenol S (BPS) | Bisphenol S (BPS) | 80-09-1 | substance | female | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 2023-12-29 | |
| Bisphenol S (BPS) | Bisphenol S (BPS) | 80-09-1 | substance | male | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 2025-01-03 | |
| Bisphenol S (BPS) | Bisphenol S (BPS) | 80-09-1 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 2025-12-08 | |
| Bitumens, extracts of steam-refined and air refined | Bitumens, extracts of steam-refined and air refined | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | CAS column: "---" | ||
| Bracken fern | Bracken fern | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | CAS column: "---" | ||
| Bromacil lithium salt | Bromacil lithium salt | 53404-19-6 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1999-05-18 | |
| Bromacil lithium salt | Bromacil lithium salt | 53404-19-6 | substance | male | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 2003-01-17 | |
| Bromate | Bromate | 15541-45-4 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2002-05-31 | |
| Bromochloroacetic acid | Bromochloroacetic acid | 5589-96-8 | substance | cancer | 0.7 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2010-04-06 | |
| 1-Bromo-3-chloropropane | 1-Bromo-3-chloropropane | 109-70-6 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2023-01-27 | |
| Bromodichloroacetic acid | Bromodichloroacetic acid | 71133-14-7 | substance | cancer | 0.95 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2016-07-29 | |
| Bromodichloromethane | Bromodichloromethane | 75-27-4 | substance | cancer | 5 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | |
| Bromoethane | Bromoethane | 74-96-4 | substance | cancer | 96 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2000-12-22 | |
| Bromoform | Bromoform | 75-25-2 | substance | cancer | 64 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1991-04-01 | |
| 1-Bromopropane (1-BP) | 1-Bromopropane (1-BP) | 106-94-5 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2016-08-05 | |
| 1-Bromopropane (1-BP) | 1-Bromopropane (1-BP) | 106-94-5 | substance | developmental, female, male | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2004-12-07 | |
| 2-Bromopropane (2-BP) | 2-Bromopropane (2-BP) | 75-26-3 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2023-08-11 | |
| 2-Bromopropane (2-BP) | 2-Bromopropane (2-BP) | 75-26-3 | substance | female, male | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2005-05-31 | |
| Bromoxynil | Bromoxynil | 1689-84-5 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1990-10-01 | |
| Bromoxynil octanoate | Bromoxynil octanoate | 1689-99-2 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1999-05-18 | |
| Butabarbital sodium | Butabarbital sodium | 143-81-7 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1992-10-01 | |
| 1,3-Butadiene | 1,3-Butadiene | 106-99-0 | substance | cancer | 0.4 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-04-01 | |
| 1,3-Butadiene | 1,3-Butadiene | 106-99-0 | substance | developmental, female, male | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2004-04-16 | |
| 1,4-Butanediol dimethanesulfonate (Busulfan) | 1,4-Butanediol dimethanesulfonate (Busulfan) | 55-98-1 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 1987-02-27 | |
| 1,4-Butanediol dimethanesulfonate (Busulfan) | 1,4-Butanediol dimethanesulfonate (Busulfan) | 55-98-1 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-01-01 | |
| Butylated hydroxyanisole | Butylated hydroxyanisole | 25013-16-5 | substance | cancer | 4000 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | |
| Butyl benzyl phthalate (BBP)d | Butyl benzyl phthalate (BBP)d | 85-68-7 | substance | developmental | 1200 (oral) µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2005-12-02 | |
| 1-Butyl glycidyl ether | 1-Butyl glycidyl ether | 2426-08-6 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2023-01-27 | |
| n-Butyl glycidyl ether | n-Butyl glycidyl ether | 2426-08-6 | substance | male | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2009-08-07 | Delisted: April 4, 2014 | until 2014-04-04 |
| beta-Butyrolactone | beta-Butyrolactone | 3068-88-0 | substance | cancer | 0.7 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-07-01 | |
| Cacodylic acid | Cacodylic acid | 75-60-5 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1996-05-01 | |
| Cadmium | Cadmium | other | developmental, male | 4.1 (oral) µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1997-05-01 | CAS column: "---" | ||
| Cadmium and cadmium compounds | Cadmium and cadmium compounds | group | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-10-01 | CAS column: "---" | ||
| Cadmium | Cadmium | other | cancer | 0.05 (inhalation) µg/day (NSRL or MADL) | Sub entry under "Cadmium and cadmium compounds" giving a safe harbor level for this member or population; type of toxicity, listing mechanism and date listed are those of the parent entry | ||
| Cannabis (marijuana) smoke | Cannabis (marijuana) smoke | other | developmental | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 2020-01-03 | CAS column: "---" | ||
| Caffeic acid | Caffeic acid | 331-39-5 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1994-10-01 | |
| Captafol | Captafol | 2425-06-1 | substance | cancer | 5 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-10-01 | |
| Captan | Captan | 133-06-2 | substance | cancer | 300 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | |
| Carbamazepine | Carbamazepine | 298-46-4 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1999-01-29 | |
| Carbaryl | Carbaryl | 63-25-2 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2010-02-05 | |
| Carbaryl [Basis for listing changed effective December 27, 2013] | Carbaryl [Basis for listing changed effective December 27, 2013] | 63-25-2 | substance | developmental, female, male | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2009-08-07 | |
| Carbazole | Carbazole | 86-74-8 | substance | cancer | 4.1 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1996-05-01 | |
| Carbon black (airborne, unbound particles of respirable size) | Carbon black (airborne, unbound particles of respirable size) | 1333-86-4 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2003-02-21 | |
| Carbon-black extracts | Carbon-black extracts | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | CAS column: "---" | ||
| Carbon disulfide | Carbon disulfide | 75-15-0 | substance | developmental, female, male | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-07-01 | |
| Carbon monoxide | Carbon monoxide | 630-08-0 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-07-01 | |
| Carbon tetrachloride | Carbon tetrachloride | 56-23-5 | substance | cancer | 5 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-10-01 | |
| Carboplatin | Carboplatin | 41575-94-4 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1990-07-01 | |
| N-Carboxymethyl-N-nitrosourea | N-Carboxymethyl-N-nitrosourea | 60391-92-6 | substance | cancer | 0.7 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 2002-01-25 | |
| Catechol | Catechol | 120-80-9 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2003-07-15 | |
| Ceramic fibers (airborne particles of respirable size) | Ceramic fibers (airborne particles of respirable size) | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-07-01 | CAS column: "---" | ||
| Certain combined chemotherapy for lymphomas | Certain combined chemotherapy for lymphomas | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 1987-02-27 | CAS column: "---" | ||
| Chenodiol | Chenodiol | 474-25-9 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1990-04-01 | |
| Chloral | Chloral | 75-87-6 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2013-09-13 | |
| Chloral hydrate | Chloral hydrate | 302-17-0 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2013-09-13 | |
| Chlorambucil | Chlorambucil | 305-03-3 | substance | cancer | 0.002 µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 1987-02-27 | |
| Chlorambucil | Chlorambucil | 305-03-3 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-01-01 | |
| Chloramphenicol | Chloramphenicol | 56-75-7 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 1989-10-01 | Delisted: January 4, 2013 | until 2013-01-04 |
| Chloramphenicol sodium succinate | Chloramphenicol sodium succinate | 982-57-0 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 2013-09-27 | |
| Chlorcyclizine hydrochloride | Chlorcyclizine hydrochloride | 1620-21-9 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1987-07-01 | |
| Chlordane | Chlordane | 57-74-9 | substance | cancer | 0.5 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-07-01 | |
| Chlordecone (Kepone) | Chlordecone (Kepone) | 143-50-0 | substance | cancer | 0.04 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Chlordecone (Kepone) | Chlordecone (Kepone) | 143-50-0 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-01-01 | |
| Chlordiazepoxide | Chlordiazepoxide | 58-25-3 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1992-01-01 | |
| Chlordiazepoxide hydrochloride | Chlordiazepoxide hydrochloride | 438-41-5 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1992-01-01 | |
| Chlordimeform | Chlordimeform | 6164-98-3 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-01-01 | |
| Chlorendic acid | Chlorendic acid | 115-28-6 | substance | cancer | 8 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-07-01 | |
| Chlorinated paraffins (Average chain length, C12;approximately 60 percent chlorine by weight) | Chlorinated paraffins (Average chain length, C12;approximately 60 percent chlorine by weight) | 108171-26-2 | substance | cancer | 8 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-07-01 | |
| p-Chloroaniline | p-Chloroaniline | 106-47-8 | substance | cancer | 1.5 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1994-10-01 | |
| p-Chloroaniline hydrochloride | p-Chloroaniline hydrochloride | 20265-96-7 | substance | cancer | 1.9 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1998-05-15 | |
| Chlorodibromomethane | Chlorodibromomethane | 124-48-1 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | Delisted: October 29, 1999 | until 1999-10-29 |
| Chloroethane (Ethyl chloride) | Chloroethane (Ethyl chloride) | 75-00-3 | substance | cancer | 150 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-07-01 | |
| 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine) | 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine) | 13010-47-4 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine) | 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine) | 13010-47-4 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1990-07-01 | |
| 1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU) | 1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU) | 13909-09-6 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-10-01 | |
| Chloroform | Chloroform | 67-66-3 | substance | cancer | 20 (oral) 40 (inhalation) µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-10-01 | |
| Chloroform [Basis for listing changed effective December 23, 2016] | Chloroform [Basis for listing changed effective December 23, 2016] | 67-66-3 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 2009-08-07 | |
| Chloromethyl methyl ether (technical grade) | Chloromethyl methyl ether (technical grade) | 107-30-2 | substance | cancer | 0.3 µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 1987-02-27 | |
| 3-Chloro-2-methylpropene | 3-Chloro-2-methylpropene | 563-47-3 | substance | cancer | 5 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-07-01 | |
| 1-Chloro-4-nitrobenzene | 1-Chloro-4-nitrobenzene | 100-00-5 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1999-10-29 | |
| 2-Chloronitrobenzene | 2-Chloronitrobenzene | 88-73-3 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2019-09-13 | |
| 4-Chloro-o-phenylenediamine | 4-Chloro-o-phenylenediamine | 95-83-0 | substance | cancer | 40 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Chloroprene | Chloroprene | 126-99-8 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2000-06-02 | |
| 2-Chloropropionic acid [Basis for listing changed effective December 20, 2013] | 2-Chloropropionic acid [Basis for listing changed effective December 20, 2013] | 598-78-7 | substance | male | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 2009-08-07 | |
| Chlorothalonil | Chlorothalonil | 1897-45-6 | substance | cancer | 41 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-01-01 | |
| p-Chloro-o-toluidine | p-Chloro-o-toluidine | 95-69-2 | substance | cancer | 3 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | |
| p-Chloro-o-toluidine, strong acid salts of | p-Chloro-o-toluidine, strong acid salts of | group | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1998-05-15 | CAS column: "---" | ||
| p-Chloro-o-toluidine, hydrochloride | p-Chloro-o-toluidine, hydrochloride | other | cancer | 3.3 µg/day (NSRL or MADL) | Sub entry under "p-Chloro-o-toluidine, strong acid salts of" giving a safe harbor level for this member or population; type of toxicity, listing mechanism and date listed are those of the parent entry | ||
| 5-Chloro-o-toluidine and its strong acid salts | 5-Chloro-o-toluidine and its strong acid salts | group | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1997-10-24 | CAS column: "---" | ||
| Chlorotrianisene | Chlorotrianisene | 569-57-3 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1996-09-01 | |
| p-chloro-α,α,α-trifluorotoluene (para-Chlorobenzotrifluoride, PCBTF) | p-chloro-α,α,α-trifluorotoluene (para-Chlorobenzotrifluoride, PCBTF) | 98-56-6 | substance | cancer | 23 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2019-06-28 | |
| Chlorozotocin | Chlorozotocin | 54749-90-5 | substance | cancer | 0.003 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1992-01-01 | |
| Chlorpyrifos | Chlorpyrifos | 2921-88-2 | substance | developmental | 0.58 (oral and inhalation) 7.2 (dermal) µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 2017-12-15 | |
| Chlorsulfuron | Chlorsulfuron | 64902-72-3 | substance | developmental, female, male | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1999-05-14 | Delisted: June 6, 2014 | until 2014-06-06 |
| Chromium (hexavalent compounds) | Chromium (hexavalent compounds) | group | cancer | 0.001 (inhalation) µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 1987-02-27 | CAS column: "---" | ||
| Chromium (hexavalent compounds) | Chromium (hexavalent compounds) | group | developmental, female, male | 8.2 (oral) µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 2008-12-19 | CAS column: "---" | ||
| Chrysene | Chrysene | 218-01-9 | substance | cancer | 0.35 (oral) µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | |
| C.I. Acid Red 114 | C.I. Acid Red 114 | 6459-94-5 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1992-07-01 | |
| C.I. Basic Red 9 monohydrochloride | C.I. Basic Red 9 monohydrochloride | 569-61-9 | substance | cancer | 3 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-07-01 | |
| C.I. Direct Blue 15 | C.I. Direct Blue 15 | 2429-74-5 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1997-08-26 | |
| C.I. Direct Blue 218 | C.I. Direct Blue 218 | 28407-37-6 | substance | cancer | 50 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1997-08-26 | |
| C.I. Disperse Yellow 3 | C.I. Disperse Yellow 3 | 2832-40-8 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 2013-02-08 | |
| C.I. Solvent Yellow 14 | C.I. Solvent Yellow 14 | 842-07-9 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1998-05-15 | |
| Ciclosporin (Cyclosporin A; Cyclosporine) | Ciclosporin (Cyclosporin A; Cyclosporine) | 59865-13-3; 79217-60-0 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1992-01-01 | |
| Cidofovir | Cidofovir | 113852-37-2 | substance | cancer, developmental, female, male | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1999-01-29 | |
| Cinnamyl anthranilate | Cinnamyl anthranilate | 87-29-6 | substance | cancer | 200 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-07-01 | |
| Cisplatin | Cisplatin | 15663-27-1 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-10-01 | |
| Citrus Red No. 2 | Citrus Red No. 2 | 6358-53-8 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 1989-10-01 | |
| Cladribine | Cladribine | 4291-63-8 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1996-09-01 | |
| Clarithromycin | Clarithromycin | 81103-11-9 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1997-05-01 | |
| Clobetasol propionate | Clobetasol propionate | 25122-46-7 | substance | developmental, female | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1998-05-15 | |
| Clofibrate | Clofibrate | 637-07-0 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1996-09-01 | |
| Clomiphene citrate | Clomiphene citrate | 50-41-9 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 2013-05-24 | |
| Clomiphene citrate | Clomiphene citrate | 50-41-9 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1990-04-01 | |
| Clorazepate dipotassium | Clorazepate dipotassium | 57109-90-7 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1992-10-01 | |
| CMNP (pyrazachlor) | CMNP (pyrazachlor) | 6814-58-0 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2015-08-25 | |
| Coal-tar pitch | Coal-tar pitch | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2023-11-17 | CAS column: "---" | ||
| Cobalt metal powder | Cobalt metal powder | 7440-48-4 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1992-07-01 | |
| Cobalt [II] oxide | Cobalt [II] oxide | 1307-96-6 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1992-07-01 | |
| Cobalt sulfate | Cobalt sulfate | 10124-43-3 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2005-05-20 | |
| Cobalt sulfate heptahydrate | Cobalt sulfate heptahydrate | 10026-24-1 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2000-06-02 | |
| Cocaine | Cocaine | 50-36-2 | substance | developmental, female | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-07-01 | |
| Coconut oil diethanolamine condensate (cocamide diethanolamine) | Coconut oil diethanolamine condensate (cocamide diethanolamine) | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2012-06-22 | CAS column: "---" | ||
| Codeine phosphate | Codeine phosphate | 52-28-8 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1998-05-15 | |
| Coke oven emissions | Coke oven emissions | other | cancer | 0.3 µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 1987-02-27 | CAS column: "---" | ||
| Colchicine | Colchicine | 64-86-8 | substance | developmental, male | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1992-10-01 | |
| Conjugated estrogens | Conjugated estrogens | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 1987-02-27 | CAS column: "---" | ||
| Conjugated estrogens | Conjugated estrogens | other | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1990-04-01 | CAS column: "---" | ||
| Creosotes | Creosotes | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-10-01 | CAS column: "---" | ||
| p-Cresidine | p-Cresidine | 120-71-8 | substance | cancer | 5 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Cumene | Cumene | 98-82-8 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2010-04-06 | |
| Cupferron | Cupferron | 135-20-6 | substance | cancer | 3 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Cyanazine | Cyanazine | 21725-46-2 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1990-04-01 | |
| Cycasin | Cycasin | 14901-08-7 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Cycloate | Cycloate | 1134-23-2 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1999-03-19 | |
| Cyclohexanol | Cyclohexanol | 108-93-0 | substance | male | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1998-11-06 | Delisted: January 25, 2002 | until 2002-01-25 |
| Cycloheximide | Cycloheximide | 66-81-9 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1989-01-01 | |
| Cyclopenta[cd]pyrene | Cyclopenta[cd]pyrene | 27208-37-3 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2011-04-29 | |
| Cyclophosphamide (anhydrous) | Cyclophosphamide (anhydrous) | 50-18-0 | substance | cancer | 1 µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 1987-02-27 | |
| Cyclophosphamide (anhydrous) | Cyclophosphamide (anhydrous) | 50-18-0 | substance | developmental, female, male | µg/day (NSRL or MADL) | Listing mechanism: SQE - developmental FR - female, male; Date listed: 1989-01-01 | |
| Cyclophosphamide (hydrated) | Cyclophosphamide (hydrated) | 6055-19-2 | substance | cancer | 1 µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 1987-02-27 | |
| Cyclophosphamide (hydrated) | Cyclophosphamide (hydrated) | 6055-19-2 | substance | developmental, female, male | µg/day (NSRL or MADL) | Listing mechanism: SQE - developmental FR - female, male; Date listed: 1989-01-01 | |
| Cyhexatin | Cyhexatin | 13121-70-5 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1989-01-01 | |
| Cytarabine | Cytarabine | 147-94-4 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-01-01 | |
| Cytembena | Cytembena | 21739-91-3 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1998-05-15 | |
| D&C Orange No. 17 | D&C Orange No. 17 | 3468-63-1 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-07-01 | |
| D&C Red No. 8 | D&C Red No. 8 | 2092-56-0 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-10-01 | |
| D&C Red No. 9 | D&C Red No. 9 | 5160-02-1 | substance | cancer | 100 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-07-01 | |
| D&C Red No. 19 | D&C Red No. 19 | 81-88-9 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-07-01 | |
| Dacarbazine | Dacarbazine | 4342-03-4 | substance | cancer | 0.01 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Dacarbazine | Dacarbazine | 4342-03-4 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1999-01-29 | |
| Daminozide | Daminozide | 1596-84-5 | substance | cancer | 40 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | |
| Danazol | Danazol | 17230-88-5 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1990-04-01 | |
| Dantron (Chrysazin; 1,8-Dihydroxyanthraquinone) | Dantron (Chrysazin; 1,8-Dihydroxyanthraquinone) | 117-10-2 | substance | cancer | 9 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1992-01-01 | |
| Daunomycin | Daunomycin | 20830-81-3 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Daunorubicin hydrochloride | Daunorubicin hydrochloride | 23541-50-6 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1990-07-01 | |
| 2,4-D butyric acid [Click here for the basis for the removal of developmental endpoint, effective June 22, 2001] | 2,4-D butyric acid [Click here for the basis for the removal of developmental endpoint, effective June 22, 2001] | 94-82-6 | substance | developmental, male | 910 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1999-06-18 | |
| DDD (Dichlorodiphenyl-dichloroethane) | DDD (Dichlorodiphenyl-dichloroethane) | 72-54-8 | substance | cancer | 2 (DDT, DDE, DDD in combination) µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-01-01 | |
| DDE (Dichlorodiphenyl-dichloroethylene) | DDE (Dichlorodiphenyl-dichloroethylene) | 72-55-9 | substance | cancer | 2 (DDT, DDE, DDD in combination) µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-01-01 | |
| DDT (Dichlorodiphenyl-trichloroethane) | DDT (Dichlorodiphenyl-trichloroethane) | 50-29-3 | substance | cancer | 2 (DDT, DDE, DDD in combination) µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-10-01 | |
| o,p'-DDT | o,p'-DDT | 789-02-6 | substance | developmental, female, male | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1998-05-15 | |
| p,p'-DDT | p,p'-DDT | 50-29-3 | substance | developmental, female, male | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1998-05-15 | |
| DDVP (Dichlorvos) | DDVP (Dichlorvos) | 62-73-7 | substance | cancer | 2 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-01-01 | |
| Demeclocycline hydrochloride (internal use) | Demeclocycline hydrochloride (internal use) | 64-73-3 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1992-01-01 | |
| Des-ethyl atrazine (DEA) | Des-ethyl atrazine (DEA) | 6190-65-4 | substance | developmental, female | 100 (oral) µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2016-07-15 | |
| Des-isopropyl atrazine (DIA) | Des-isopropyl atrazine (DIA) | 1007-28-9 | substance | developmental, female | 100 (oral) µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2016-07-15 | |
| N,N'-Diacetylbenzidine | N,N'-Diacetylbenzidine | 613-35-4 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 1989-10-01 | |
| 2,4-Diaminoanisole | 2,4-Diaminoanisole | 615-05-4 | substance | cancer | 30 µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1990-10-01 | |
| 2,4-Diaminoanisole sulfate | 2,4-Diaminoanisole sulfate | 39156-41-7 | substance | cancer | 50 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| 2,4-Diamino-6-chloro-s-triazine (DACT) | 2,4-Diamino-6-chloro-s-triazine (DACT) | 3397-62-4 | substance | developmental, female | 100 (oral) µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2016-07-15 | |
| 4,4'-Diaminodiphenyl ether (4,4'-Oxydianiline) | 4,4'-Diaminodiphenyl ether (4,4'-Oxydianiline) | 101-80-4 | substance | cancer | 5 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| 2,4-Diaminotoluene | 2,4-Diaminotoluene | 95-80-7 | substance | cancer | 0.2 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Diaminotoluene (mixed) Delisted November, 20 2015 [Click here for the basis for delisting] | Diaminotoluene (mixed) Delisted November, 20 2015 [Click here for the basis for delisting] | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | CAS column: "---" | ||
| Diazepam | Diazepam | 439-14-5 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1992-01-01 | |
| Diazoaminobenzene | Diazoaminobenzene | 136-35-6 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2005-05-20 | |
| Diazoxide | Diazoxide | 364-98-7 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 2001-02-27 | |
| Dibenz[a,h]acridine | Dibenz[a,h]acridine | 226-36-8 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Dibenz[a,j]acridine | Dibenz[a,j]acridine | 224-42-0 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Dibenzanthracenes | Dibenzanthracenes | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 2014-12-26 | CAS column: "---" | ||
| Dibenz[a,c]anthracene | Dibenz[a,c]anthracene | 215-58-7 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 2014-12-26 | |
| Dibenz[a,h]anthracene | Dibenz[a,h]anthracene | 53-70-3 | substance | cancer | 0.2 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Dibenz[a,j]anthracene | Dibenz[a,j]anthracene | 224-41-9 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 2014-12-26 | |
| 7H-Dibenzo[c,g]carbazole | 7H-Dibenzo[c,g]carbazole | 194-59-2 | substance | cancer | 0.0030 (oral) µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Dibenzo[a,e]pyrene | Dibenzo[a,e]pyrene | 192-65-4 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Dibenzo[a,h]pyrene | Dibenzo[a,h]pyrene | 189-64-0 | substance | cancer | 0.0054 (oral) µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Dibenzo[a,i]pyrene | Dibenzo[a,i]pyrene | 189-55-9 | substance | cancer | 0.0050 (oral) µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Dibenzo[a,l]pyrene | Dibenzo[a,l]pyrene | 191-30-0 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Dibromoacetic acid | Dibromoacetic acid | 631-64-1 | substance | cancer | 2.8 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2008-06-17 | |
| Dibromoacetonitrile | Dibromoacetonitrile | 3252-43-5 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2011-05-03 | |
| 1,2-Dibromo-3-chloropropane (DBCP) | 1,2-Dibromo-3-chloropropane (DBCP) | 96-12-8 | substance | cancer | 0.1 µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1987-07-01 | |
| 1,2-Dibromo-3-chloropropane (DBCP) [Basis for listing changed effective November 22, 2013] | 1,2-Dibromo-3-chloropropane (DBCP) [Basis for listing changed effective November 22, 2013] | 96-12-8 | substance | male | 3.1 (oral) 4.3 (inhalation) µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1987-02-27 | |
| 2,3-Dibromo-1-propanol | 2,3-Dibromo-1-propanol | 96-13-9 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1994-10-01 | |
| Dichloroacetic acid | Dichloroacetic acid | 79-43-6 | substance | cancer | 17 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1996-05-01 | |
| Dichloroacetic acid | Dichloroacetic acid | 79-43-6 | substance | developmental, male | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2009-08-07 | |
| p-Dichlorobenzene | p-Dichlorobenzene | 106-46-7 | substance | cancer | 20 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-01-01 | |
| 3,3'-Dichlorobenzidine | 3,3'-Dichlorobenzidine | 91-94-1 | substance | cancer | 0.6 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-10-01 | |
| 3,3'-Dichlorobenzidine dihydrochloride | 3,3'-Dichlorobenzidine dihydrochloride | 612-83-9 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1998-05-15 | |
| 1,1-Dichloro-2,2-bis(p-chloropheny)ethylene (DDE) | 1,1-Dichloro-2,2-bis(p-chloropheny)ethylene (DDE) | 72-55-9 | substance | developmental, male | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2010-03-30 | |
| 1,4-Dichloro-2-butene | 1,4-Dichloro-2-butene | 764-41-0 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | |
| 3,3'-Dichloro-4,4'-diamino-diphenyl ether | 3,3'-Dichloro-4,4'-diamino-diphenyl ether | 28434-86-8 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| 1,1-Dichloroethane | 1,1-Dichloroethane | 75-34-3 | substance | cancer | 100 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | |
| Dichloromethane (Methylene chloride) | Dichloromethane (Methylene chloride) | 75-09-2 | substance | cancer | 50 200 (inhalation) µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-04-01 | |
| 1,4-Dichloro-2-nitrobenzene | 1,4-Dichloro-2-nitrobenzene | 89-61-2 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2019-09-13 | |
| 2,4-Dichloro-1-nitrobenzene | 2,4-Dichloro-1-nitrobenzene | 611-06-3 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2019-09-13 | |
| Dichlorophene | Dichlorophene | 97-23-4 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1999-04-27 | |
| Dichlorphenamide | Dichlorphenamide | 120-97-8 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 2001-02-27 | |
| 1,2-Dichloropropane | 1,2-Dichloropropane | 78-87-5 | substance | cancer | 9.7 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | |
| 1,3-Dichloro-2-propanol (1,3-DCP) | 1,3-Dichloro-2-propanol (1,3-DCP) | 96-23-1 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 2010-10-08 | |
| 1,3-Dichloropropene | 1,3-Dichloropropene | 542-75-6 | substance | cancer | 3.7 (oral and inhalation) µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-01-01 | |
| Diclofop-methyl | Diclofop-methyl | 51338-27-3 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2010-04-06 | |
| Diclofop methyl | Diclofop methyl | 51338-27-3 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1999-03-05 | |
| Dicumarol | Dicumarol | 66-76-2 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1992-10-01 | |
| Dieldrin | Dieldrin | 60-57-1 | substance | cancer | 0.04 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-07-01 | |
| Dienestrol | Dienestrol | 84-17-3 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 1990-01-01 | Delisted: January 4, 2013 | until 2013-01-04 |
| Diepoxybutane | Diepoxybutane | 1464-53-5 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Diesel engine exhaust | Diesel engine exhaust | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-10-01 | CAS column: "---" | ||
| Diethanolamine | Diethanolamine | 111-42-2 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2012-06-22 | |
| Di(2-ethylhexyl)phthalate (DEHP) | Di(2-ethylhexyl)phthalate (DEHP) | 117-81-7 | substance | cancer | 310 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Di(2-ethylhexyl)phthalate (DEHP) | Di(2-ethylhexyl)phthalate (DEHP) | 117-81-7 | substance | developmental, male | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2003-10-24 | |
| Adult | Adult | other | developmental, male | 4200 (intravenous) µg/day (NSRL or MADL) | Sub entry under "Di(2-ethylhexyl)phthalate (DEHP)" giving a safe harbor level for this member or population; type of toxicity, listing mechanism and date listed are those of the parent entry | b: Levels for male children and adolescents were calculated by application of the default bodyweights specified in Section 25703(a)(8) to the procedure specified in Sections 25801 and 25803 | ||
| Infant boys, age 29 days to 24 months | Infant boys, age 29 days to 24 months | other | developmental, male | 600 (intravenous) µg/day (NSRL or MADL) | Sub entry under "Di(2-ethylhexyl)phthalate (DEHP)" giving a safe harbor level for this member or population; type of toxicity, listing mechanism and date listed are those of the parent entry | b: Levels for male children and adolescents were calculated by application of the default bodyweights specified in Section 25703(a)(8) to the procedure specified in Sections 25801 and 25803 | ||
| Neonatal infant boys, age 0 to 28 days | Neonatal infant boys, age 0 to 28 days | other | developmental, male | 210 (intravenous) µg/day (NSRL or MADL) | Sub entry under "Di(2-ethylhexyl)phthalate (DEHP)" giving a safe harbor level for this member or population; type of toxicity, listing mechanism and date listed are those of the parent entry | b: Levels for male children and adolescents were calculated by application of the default bodyweights specified in Section 25703(a)(8) to the procedure specified in Sections 25801 and 25803 | ||
| Adult | Adult | other | developmental, male | 410 (oral) µg/day (NSRL or MADL) | Sub entry under "Di(2-ethylhexyl)phthalate (DEHP)" giving a safe harbor level for this member or population; type of toxicity, listing mechanism and date listed are those of the parent entry | b: Levels for male children and adolescents were calculated by application of the default bodyweights specified in Section 25703(a)(8) to the procedure specified in Sections 25801 and 25803 | ||
| Infant boys, age 29 days to 24 months | Infant boys, age 29 days to 24 months | other | developmental, male | 58 (oral) µg/day (NSRL or MADL) | Sub entry under "Di(2-ethylhexyl)phthalate (DEHP)" giving a safe harbor level for this member or population; type of toxicity, listing mechanism and date listed are those of the parent entry | b: Levels for male children and adolescents were calculated by application of the default bodyweights specified in Section 25703(a)(8) to the procedure specified in Sections 25801 and 25803 | ||
| Neonatal infant boys, age 0 to 28 days | Neonatal infant boys, age 0 to 28 days | other | developmental, male | 20 (oral) µg/day (NSRL or MADL) | Sub entry under "Di(2-ethylhexyl)phthalate (DEHP)" giving a safe harbor level for this member or population; type of toxicity, listing mechanism and date listed are those of the parent entry | b: Levels for male children and adolescents were calculated by application of the default bodyweights specified in Section 25703(a)(8) to the procedure specified in Sections 25801 and 25803 | ||
| 1,2-Diethylhydrazine | 1,2-Diethylhydrazine | 1615-80-1 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Diethylstilbestrol (DES) | Diethylstilbestrol (DES) | 56-53-1 | substance | cancer | 0.002 µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 1987-02-27 | |
| Diethylstilbestrol (DES) | Diethylstilbestrol (DES) | 56-53-1 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1987-07-01 | |
| Diethyl sulfate | Diethyl sulfate | 64-67-5 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Diflunisal | Diflunisal | 22494-42-4 | substance | developmental, female | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1999-01-29 | |
| Diglycidyl ether | Diglycidyl ether | 2238-07-5 | substance | male | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2009-08-07 | Delisted: April 4, 2014 | until 2014-04-04 |
| Diglycidyl resorcinol ether (DGRE) | Diglycidyl resorcinol ether (DGRE) | 101-90-6 | substance | cancer | 0.4 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-07-01 | |
| Dihydroergotamine mesylate | Dihydroergotamine mesylate | 6190-39-2 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1997-05-01 | |
| Dihydrosafrole | Dihydrosafrole | 94-58-6 | substance | cancer | 20 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Di-isodecyl phthalate (DIDP) | Di-isodecyl phthalate (DIDP) | 68515-49-1/ 26761-40-0 | substance | developmental | 2200 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2007-04-20 | |
| Diisononyl phthalate (DINP) | Diisononyl phthalate (DINP) | other | cancer | 146 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 2013-12-20 | CAS column: "---" | ||
| Diisopropyl sulfate | Diisopropyl sulfate | 2973-10-6 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1993-04-01 | |
| Diltiazem hydrochloride | Diltiazem hydrochloride | 33286-22-5 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 2001-02-27 | |
| 3,3'-Dimethoxybenzidine (o-Dianisidine) | 3,3'-Dimethoxybenzidine (o-Dianisidine) | 119-90-4 | substance | cancer | 0.15 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| 3,3'-Dimethoxybenzidine dihydrochloride | 3,3'-Dimethoxybenzidine dihydrochloride | 20325-40-0 | substance | cancer | 0.19 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-10-01 | |
| 3,3'-Dimethoxybenzidine-based dyes metabolized to 3,3'-dimethoxybenzidine | 3,3'-Dimethoxybenzidine-based dyes metabolized to 3,3'-dimethoxybenzidine | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2004-06-11 | CAS column: "---" | ||
| N,N-Dimethylacetamide | N,N-Dimethylacetamide | 127-19-5 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2019-09-13 | |
| N,N-Dimethylacetamide [Click here for the basis for addition of male reproductive endpoint, effective December 20, 2013] | N,N-Dimethylacetamide [Click here for the basis for addition of male reproductive endpoint, effective December 20, 2013] | 127-19-5 | substance | developmental, male | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 2010-05-21 | |
| 4-Dimethylaminoazobenzene | 4-Dimethylaminoazobenzene | 60-11-7 | substance | cancer | 0.2 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| trans-2-[(Dimethylamino)methylimino]-5-[2-(5-nitro-2-furyl)vinyl]-1,3,4-oxadiazole | trans-2-[(Dimethylamino)methylimino]-5-[2-(5-nitro-2-furyl)vinyl]-1,3,4-oxadiazole | 55738-54-0 | substance | cancer | 2 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| 7,12-Dimethylbenz(a)anthracene | 7,12-Dimethylbenz(a)anthracene | 57-97-6 | substance | cancer | 0.003 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | |
| 3,3'-Dimethylbenzidine (ortho-Tolidine) | 3,3'-Dimethylbenzidine (ortho-Tolidine) | 119-93-7 | substance | cancer | 0.044 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| 3,3'-Dimethylbenzidine-based dyes metabolized to 3,3'-dimethylbenzidine | 3,3'-Dimethylbenzidine-based dyes metabolized to 3,3'-dimethylbenzidine | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2004-06-11 | CAS column: "---" | ||
| 3,3'-Dimethylbenzidine dihydrochloride | 3,3'-Dimethylbenzidine dihydrochloride | 612-82-8 | substance | cancer | 0.059 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1992-04-01 | |
| Dimethylcarbamoyl chloride | Dimethylcarbamoyl chloride | 79-44-7 | substance | cancer | 0.05 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| N,N-Dimethylformamide | N,N-Dimethylformamide | 68-12-2 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2017-10-27 | |
| 1,1-Dimethylhydrazine (UDMH) | 1,1-Dimethylhydrazine (UDMH) | 57-14-7 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 1989-10-01 | |
| 1,2-Dimethylhydrazine | 1,2-Dimethylhydrazine | 540-73-8 | substance | cancer | 0.001 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Dimethyl hydrogen phosphite | Dimethyl hydrogen phosphite | 868-85-9 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2023-08-11 | |
| 2,6-Dimethyl-N-nitrosomorpholine (DMNM) | 2,6-Dimethyl-N-nitrosomorpholine (DMNM) | 1456-28-6 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 2013-02-08 | |
| Dimethyl sulfate | Dimethyl sulfate | 77-78-1 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| N,N-Dimethyl-p-toluidine | N,N-Dimethyl-p-toluidine | 99-97-8 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2014-05-02 | |
| Dimethylvinylchloride | Dimethylvinylchloride | 513-37-1 | substance | cancer | 20 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-07-01 | |
| Di-n-butyl phthalate (DBP) | Di-n-butyl phthalate (DBP) | 84-74-2 | substance | developmental, female, male | 8.7 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2005-12-02 | |
| Di-n-hexyl phthalate (DnHP) | Di-n-hexyl phthalate (DnHP) | 84-75-3 | substance | female, male | 2200 (oral) µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2005-12-02 | |
| m-Dinitrobenzene | m-Dinitrobenzene | 99-65-0 | substance | male | 38 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-07-01 | |
| o-Dinitrobenzene | o-Dinitrobenzene | 528-29-0 | substance | male | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-07-01 | |
| p-Dinitrobenzene | p-Dinitrobenzene | 100-25-4 | substance | male | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-07-01 | |
| 3,7-Dinitrofluoranthene | 3,7-Dinitrofluoranthene | 105735-71-5 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1997-08-26 | |
| 3,9-Dinitrofluoranthene | 3,9-Dinitrofluoranthene | 22506-53-2 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1997-08-26 | |
| 1,3-Dinitropyrene | 1,3-Dinitropyrene | 75321-20-9 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2012-11-02 | |
| 1,6-Dinitropyrene | 1,6-Dinitropyrene | 42397-64-8 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-10-01 | |
| 1,8-Dinitropyrene | 1,8-Dinitropyrene | 42397-65-9 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-10-01 | |
| 2,4-Dinitrotoluene | 2,4-Dinitrotoluene | 121-14-2 | substance | cancer | 2 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-07-01 | |
| 2,4-Dinitrotoluene | 2,4-Dinitrotoluene | 121-14-2 | substance | male | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1999-08-20 | |
| 2,6-Dinitrotoluene | 2,6-Dinitrotoluene | 606-20-2 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1995-07-01 | |
| 2,6-Dinitrotoluene | 2,6-Dinitrotoluene | 606-20-2 | substance | male | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1999-08-20 | |
| Dinitrotoluene (technical grade) | Dinitrotoluene (technical grade) | other | female, male | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1999-08-20 | CAS column: "---" | ||
| Dinitrotoluene mixture, 2,4-/2,6- | Dinitrotoluene mixture, 2,4-/2,6- | group | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1996-05-01 | CAS column: "---" | ||
| Dinocap | Dinocap | 39300-45-3 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1990-04-01 | |
| Dinoseb | Dinoseb | 88-85-7 | substance | developmental, male | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1989-01-01 | |
| Di-n-propyl isocinchomeronate (MGK Repellent 326) | Di-n-propyl isocinchomeronate (MGK Repellent 326) | 136-45-8 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1996-05-01 | |
| 1,4-Dioxane | 1,4-Dioxane | 123-91-1 | substance | cancer | 30 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Diphenylhydantoin (Phenytoin) | Diphenylhydantoin (Phenytoin) | 57-41-0 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Diphenylhydantoin (Phenytoin) | Diphenylhydantoin (Phenytoin) | 57-41-0 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-07-01 | |
| Diphenylhydantoin (Phenytoin), sodium salt | Diphenylhydantoin (Phenytoin), sodium salt | 630-93-3 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Direct Black 38 (technical grade) | Direct Black 38 (technical grade) | 1937-37-7 | substance | cancer | 0.09 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Direct Blue 6 (technical grade) | Direct Blue 6 (technical grade) | 2602-46-2 | substance | cancer | 0.09 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Direct Brown 95 (technical grade) | Direct Brown 95 (technical grade) | 16071-86-6 | substance | cancer | 0.1 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-10-01 | |
| Disodium cyanodithioimidocarbonate | Disodium cyanodithioimidocarbonate | 138-93-2 | substance | developmental | 56 (oral) 170 (oral) as 32% pesticidal formulation µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1999-03-30 | |
| Disperse Blue 1 | Disperse Blue 1 | 2475-45-8 | substance | cancer | 200 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-10-01 | |
| Diuron | Diuron | 330-54-1 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2002-05-31 | |
| Doxorubicin hydrochloride (Adriamycin) | Doxorubicin hydrochloride (Adriamycin) | 25316-40-9 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-07-01 | |
| Doxorubicin hydrochloride (Adriamycin) | Doxorubicin hydrochloride (Adriamycin) | 25316-40-9 | substance | developmental, male | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1999-01-29 | |
| Doxycycline (internal use) | Doxycycline (internal use) | 564-25-0 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1990-07-01 | |
| Doxycycline calcium (internal use) | Doxycycline calcium (internal use) | 94088-85-4 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1992-01-01 | |
| Doxycycline hyclate (internal use) | Doxycycline hyclate (internal use) | 24390-14-5 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1991-10-01 | |
| Doxycycline monohydrate (internal use) | Doxycycline monohydrate (internal use) | 17086-28-1 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1991-10-01 | |
| 2,4-DP (dichloroprop) | 2,4-DP (dichloroprop) | 120-36-5 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1999-04-27 | Delisted: January 25, 2002 | until 2002-01-25 |
| Emissions from combustion of coal | Emissions from combustion of coal | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2013-08-07 | CAS column: "---" | ||
| Emissions from high-temperature unrefined rapeseed oil | Emissions from high-temperature unrefined rapeseed oil | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2014-01-03 | CAS column: "---" | ||
| Endrin | Endrin | 72-20-8 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1998-05-15 | |
| Environmental tobacco smoke (ETS) | Environmental tobacco smoke (ETS) | other | developmental | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 2006-06-09 | CAS column: "---" | ||
| Epichlorohydrin | Epichlorohydrin | 106-89-8 | substance | cancer | 9 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-10-01 | |
| Epichlorohydrin | Epichlorohydrin | 106-89-8 | substance | male | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1996-09-01 | |
| Epoxiconazole | Epoxiconazole | 135319-73-2 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2011-04-15 | |
| Ergotamine tartrate | Ergotamine tartrate | 379-79-3 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1990-04-01 | |
| Erionite | Erionite | 12510-42-8; 66733-21-9 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-10-01 | |
| Estradiol 17B | Estradiol 17B | 50-28-2 | substance | cancer | 0.02 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Estragole | Estragole | 140-67-0 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1999-10-29 | |
| Estrogens, steroidal | Estrogens, steroidal | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2005-08-19 | CAS column: "---" | ||
| Estrogen-progestogen (combined) used as menopausal therapy | Estrogen-progestogen (combined) used as menopausal therapy | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2011-11-04 | CAS column: "---" | ||
| Estrone | Estrone | 53-16-7 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Estropipate | Estropipate | 7280-37-7 | substance | cancer, developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1997-08-26 | |
| Ethinylestradiol | Ethinylestradiol | 57-63-6 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Ethionamide | Ethionamide | 536-33-4 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1997-08-26 | |
| Ethoprop | Ethoprop | 13194-48-4 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2001-02-27 | |
| Ethyl acrylate | Ethyl acrylate | 140-88-5 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-07-01 | |
| Ethyl alcohol in alcoholic beverages | Ethyl alcohol in alcoholic beverages | other | developmental | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-10-01 | CAS column: "---" | ||
| Ethylbenzene | Ethylbenzene | 100-41-4 | substance | cancer | 54 (inhalation) 41 (oral) µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2004-06-11 | |
| Ethyl-tert-butyl ether | Ethyl-tert-butyl ether | 637-92-3 | substance | male | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2009-12-18 | Delisted: December 13, 2013 | until 2013-12-13 |
| Ethyl dipropylthiocarbamate | Ethyl dipropylthiocarbamate | 759-94-4 | substance | developmental | 700 (oral and inhalation) 6700 (dermal) µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1999-04-27 | |
| Ethyl-4,4'-dichlorobenzilate | Ethyl-4,4'-dichlorobenzilate | 510-15-6 | substance | cancer | 7 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | |
| Ethylene dibromide | Ethylene dibromide | 106-93-4 | substance | cancer | 0.2 (oral) 3 (inhalation) µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1987-07-01 | |
| Ethylene dibromide | Ethylene dibromide | 106-93-4 | substance | developmental, male | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1998-05-15 | |
| Ethylene dichloride (1,2-Dichloroethane) | Ethylene dichloride (1,2-Dichloroethane) | 107-06-2 | substance | cancer | 10 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-10-01 | |
| Ethylene glycol (ingested) | Ethylene glycol (ingested) | 107-21-1 | substance | developmental | 8700 (oral) µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2015-06-19 | |
| Ethylene glycol monoethyl ether | Ethylene glycol monoethyl ether | 110-80-5 | substance | developmental, male | 750 (oral) 960 (inhalation) µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-01-01 | |
| Ethylene glycol monoethyl ether acetate | Ethylene glycol monoethyl ether acetate | 111-15-9 | substance | developmental, male | 1100 (oral) 1400 (inhalation) µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1993-01-01 | |
| Ethylene glycol monomethyl ether | Ethylene glycol monomethyl ether | 109-86-4 | substance | developmental, male | 63 (oral) µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-01-01 | |
| Ethylene glycol monomethyl ether acetate | Ethylene glycol monomethyl ether acetate | 110-49-6 | substance | developmental, male | 98 (oral) µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1993-01-01 | |
| Ethyleneimine (Aziridine) | Ethyleneimine (Aziridine) | 151-56-4 | substance | cancer | 0.01 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Ethylene oxide | Ethylene oxide | 75-21-8 | substance | cancer | 2 µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1987-07-01 | |
| Ethylene oxide [Basis for listing changed effective November 22, 2013] | Ethylene oxide [Basis for listing changed effective November 22, 2013] | 75-21-8 | substance | female | 20 µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1987-02-27 | |
| Ethylene oxide [Basis for listing changed effective November 22, 2013] | Ethylene oxide [Basis for listing changed effective November 22, 2013] | 75-21-8 | substance | developmental, male | 20 µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 2009-08-07 | |
| Ethylene thiourea | Ethylene thiourea | 96-45-7 | substance | cancer | 20 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1988-01-01 | |
| Ethylene thiourea | Ethylene thiourea | 96-45-7 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1993-01-01 | |
| 2-Ethylhexanoic acid | 2-Ethylhexanoic acid | 149-57-5 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2009-08-07 | Delisted: December 13, 2013 | until 2013-12-13 |
| 2-Ethylhexyl acrylate | 2-Ethylhexyl acrylate | 103-11-7 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2021-12-17 | |
| Ethyl methanesulfonate | Ethyl methanesulfonate | 62-50-0 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Etodolac | Etodolac | 41340-25-4 | substance | developmental, female | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1999-08-20 | |
| Etoposide | Etoposide | 33419-42-0 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2011-11-04 | |
| Etoposide | Etoposide | 33419-42-0 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1990-07-01 | |
| Etoposide in combination with cisplatin and bleomycin | Etoposide in combination with cisplatin and bleomycin | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2011-11-04 | CAS column: "---" | ||
| Etretinate | Etretinate | 54350-48-0 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1987-07-01 | |
| Fenoxaprop ethyl | Fenoxaprop ethyl | 66441-23-4 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1999-03-26 | |
| Fenoxycarb | Fenoxycarb | 72490-01-8 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2000-06-02 | |
| Filgrastim | Filgrastim | 121181-53-1 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 2001-02-27 | |
| Fluazifop butyl | Fluazifop butyl | 69806-50-4 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1998-11-06 | |
| Flunisolide | Flunisolide | 3385-03-3 | substance | developmental, female | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1998-05-15 | |
| Fluorouracil | Fluorouracil | 51-21-8 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-01-01 | |
| Fluoro-edenite fibrous amphibole | Fluoro-edenite fibrous amphibole | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2023-11-17 | CAS column: "---" | ||
| Fluoxymesterone | Fluoxymesterone | 76-43-7 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1990-04-01 | |
| Flurazepam hydrochloride | Flurazepam hydrochloride | 1172-18-5 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1992-10-01 | |
| Flurbiprofen | Flurbiprofen | 5104-49-4 | substance | developmental, female | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1999-08-20 | |
| Flutamide | Flutamide | 13311-84-7 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1990-07-01 | |
| Fluticasone propionate | Fluticasone propionate | 80474-14-2 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1998-05-15 | |
| Fluvalinate | Fluvalinate | 69409-94-5 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1998-11-06 | |
| Folpet | Folpet | 133-07-3 | substance | cancer | 200 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-01-01 | |
| Formaldehyde (gas) | Formaldehyde (gas) | 50-00-0 | substance | cancer | 40 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| 2-(2-Formylhydrazino)-4-(5-nitro-2-furyl)thiazole | 2-(2-Formylhydrazino)-4-(5-nitro-2-furyl)thiazole | 3570-75-0 | substance | cancer | 0.3 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Fumonisin B1 | Fumonisin B1 | 116355-83-0 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2003-11-14 | |
| Furan | Furan | 110-00-9 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1993-10-01 | |
| Furazolidone | Furazolidone | 67-45-8 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | |
| Furfuryl alcohol | Furfuryl alcohol | 98-00-0 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 2016-09-30 | |
| Furmecyclox | Furmecyclox | 60568-05-0 | substance | cancer | 20 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | |
| Fusarin C | Fusarin C | 79748-81-5 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1995-07-01 | |
| Gallium arsenide | Gallium arsenide | 1303-00-0 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2008-08-01 | |
| Ganciclovir | Ganciclovir | 82410-32-0 | substance | cancer, developmental, male | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1997-08-26 | |
| Ganciclovir sodium | Ganciclovir sodium | 107910-75-8 | substance | developmental, male | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1997-08-26 | |
| Gasoline engine exhaust (condensates/extracts) | Gasoline engine exhaust (condensates/extracts) | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-10-01 | CAS column: "---" | ||
| Gemfibrozil | Gemfibrozil | 25812-30-0 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 2000-12-22 | |
| Gemfibrozil | Gemfibrozil | 25812-30-0 | substance | female, male | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1999-08-20 | |
| Gentian violet (Crystal violet) | Gentian violet (Crystal violet) | 548-62-9 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 2018-11-23 | |
| Glass wool fibers (inhalable and biopersistent) | Glass wool fibers (inhalable and biopersistent) | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-07-01 | CAS column: "---" | ||
| Glu-P-1 (2-Amino-6-methyldipyrido[1,2- a:3',2'-d]imidazole) | Glu-P-1 (2-Amino-6-methyldipyrido[1,2- a:3',2'-d]imidazole) | 67730-11-4 | substance | cancer | 0.1 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | |
| Glu-P-2 (2-Aminodipyrido[1,2-a:3',2'-d]imidazole) | Glu-P-2 (2-Aminodipyrido[1,2-a:3',2'-d]imidazole) | 67730-10-3 | substance | cancer | 0.5 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | |
| Glycidaldehyde | Glycidaldehyde | 765-34-4 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Glycidol | Glycidol | 556-52-5 | substance | cancer | 0.54 µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-07-01 | |
| Glycidyl methacrylate | Glycidyl methacrylate | 106-91-2 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2023-01-27 | |
| Glyphosate | Glyphosate | 1071-83-6 | substance | cancer | 1100 µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2017-07-07 | |
| Goldenseal root powder | Goldenseal root powder | other | cancer | µg/day (NSRL or MADL) | Listing mechanism: LC; Date listed: 2015-12-04 | CAS column: "---" | ||
| Goserelin acetate | Goserelin acetate | 65807-02-5 | substance | developmental, female, male | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1997-08-26 | |
| Griseofulvin | Griseofulvin | 126-07-8 | substance | cancer | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1990-01-01 | |
| Gyromitrin (Acetaldehyde methylformylhydrazone) | Gyromitrin (Acetaldehyde methylformylhydrazone) | 16568-02-8 | substance | cancer | 0.07 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-01-01 | |
| Halazepam | Halazepam | 23092-17-3 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1990-07-01 | |
| Halobetasol propionate | Halobetasol propionate | 66852-54-8 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1999-08-20 | |
| Haloperidol | Haloperidol | 52-86-8 | substance | developmental, female | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1999-01-29 | |
| Halothane | Halothane | 151-67-7 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: FR; Date listed: 1996-09-01 | |
| HC Blue 1 | HC Blue 1 | 2784-94-3 | substance | cancer | 10 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1989-07-01 | |
| Heptachlor | Heptachlor | 76-44-8 | substance | cancer | 0.2 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-07-01 | |
| Heptachlor | Heptachlor | 76-44-8 | substance | developmental | µg/day (NSRL or MADL) | Listing mechanism: AB; Date listed: 1999-08-20 | |
| Heptachlor epoxide | Heptachlor epoxide | 1024-57-3 | substance | cancer | 0.08 µg/day (NSRL or MADL) | Listing mechanism: SQE; Date listed: 1988-07-01 |
Official source
Entries are copied exactly as published. Not legal advice; always check the official text.